1. Home
  2. OMER vs GHM Comparison

OMER vs GHM Comparison

Compare OMER & GHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OMER
  • GHM
  • Stock Information
  • Founded
  • OMER 1994
  • GHM 1936
  • Country
  • OMER United States
  • GHM United States
  • Employees
  • OMER N/A
  • GHM N/A
  • Industry
  • OMER Biotechnology: Pharmaceutical Preparations
  • GHM Industrial Machinery/Components
  • Sector
  • OMER Health Care
  • GHM Industrials
  • Exchange
  • OMER Nasdaq
  • GHM Nasdaq
  • Market Cap
  • OMER 397.1M
  • GHM 409.5M
  • IPO Year
  • OMER 2009
  • GHM N/A
  • Fundamental
  • Price
  • OMER $3.21
  • GHM $45.16
  • Analyst Decision
  • OMER Strong Buy
  • GHM Buy
  • Analyst Count
  • OMER 5
  • GHM 1
  • Target Price
  • OMER $18.00
  • GHM $35.00
  • AVG Volume (30 Days)
  • OMER 808.8K
  • GHM 99.5K
  • Earning Date
  • OMER 08-06-2025
  • GHM 06-09-2025
  • Dividend Yield
  • OMER N/A
  • GHM N/A
  • EPS Growth
  • OMER N/A
  • GHM 164.29
  • EPS
  • OMER N/A
  • GHM 1.11
  • Revenue
  • OMER N/A
  • GHM $209,896,000.00
  • Revenue This Year
  • OMER N/A
  • GHM $10.67
  • Revenue Next Year
  • OMER $468.75
  • GHM $9.35
  • P/E Ratio
  • OMER N/A
  • GHM $40.59
  • Revenue Growth
  • OMER N/A
  • GHM 13.13
  • 52 Week Low
  • OMER $2.97
  • GHM $24.78
  • 52 Week High
  • OMER $13.60
  • GHM $52.00
  • Technical
  • Relative Strength Index (RSI)
  • OMER 34.64
  • GHM 65.26
  • Support Level
  • OMER $2.97
  • GHM $45.48
  • Resistance Level
  • OMER $4.06
  • GHM $48.05
  • Average True Range (ATR)
  • OMER 0.26
  • GHM 1.85
  • MACD
  • OMER 0.10
  • GHM 0.01
  • Stochastic Oscillator
  • OMER 22.02
  • GHM 51.74

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

About GHM Graham Corporation

Graham Corporation designs and manufactures mission-critical fluid, power, heat transfer, and vacuum technologies for the defense, space, energy, and process industries. The company also services and sells spare parts for its equipment. It designs and manufactures custom-engineered vacuum, heat transfer, cryogenic pump and turbomachinery technologies.

Share on Social Networks: